Company · CIK 0001401667 · SIC 2834 — Pharmaceutical Preparations · Nasdaq
PUMA BIOTECHNOLOGY, INC. · PBYI
Insider activity reported against this company. All insider holders · On EDGAR ↗
Reported at this company — common stock
| Trade | Reported (ET) | Insider | Shares | Avg price | Total | Owned after | Δ stake | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 14, 2026 SForm 4 → | Sep 16, 9:13 pm EDT | Troy Edward WilsonDirector | 5,000 | $9.10 | $45,500 | 54,750 | −8.37% | 10b5-1 |
| Sep 14, 2026 SForm 4 → | Sep 16, 9:06 pm EDT | Alessandra CesanoDirector | 62,150 | $9.12 | $566,994 | 56,700 | −52.3% | 10b5-1 |
| Sep 14, 2026 MForm 4 → | Sep 16, 9:06 pm EDT | Alessandra CesanoDirector | 50,000 | $2.93 | $146,500 | 118,850 | — | 10b5-1 |
| Jul 6, 2026 SForm 4 → | Jul 8, 8:21 pm EDT | Alan H AuerbachPresident and CEO, Director, 10% Owner | 44,058 | $8.26 | $364,051 | 7,261,671 | −0.60% | 10b5-1 |
| Jul 6, 2026 SForm 4 → | Jul 8, 8:19 pm EDT | Douglas M HuntSee Remarks | 8,460 | $8.26 | $69,905 | 196,841 | −4.12% | 10b5-1 |
| Jul 6, 2026 SForm 4 → | Jul 8, 8:18 pm EDT | Maximo F NouguesChief Financial Officer | 9,386 | $8.26 | $77,557 | 230,637 | −3.91% | 10b5-1 |
| Jun 12, 2026 SForm 4 → | Jun 15, 8:16 pm EDT | Troy Edward WilsonDirector | 10,800 | $7.20 | $77,748 | 59,750 | −15.3% | 10b5-1 |
| Jun 12, 2026 SForm 4 → | Jun 15, 8:14 pm EDT | Brian M StuglikDirector | 8,100 | $7.20 | $58,311 | 113,858 | −6.64% | 10b5-1 |
| Jun 12, 2026 SForm 4 → | Jun 15, 8:13 pm EDT | Adrian SenderowiczDirector | 27,000 | $7.20 | $194,311 | 27,000 | −50.0% | 10b5-1 |
| Jun 12, 2026 SForm 4 → | Jun 15, 8:10 pm EDT | Jay M MoyesDirector | 22,000 | $7.22 | $158,796 | 58,322 | −27.4% | 10b5-1 |
| Jun 12, 2026 SForm 4 → | Jun 15, 8:09 pm EDT | Allison DorvalDirector | 11,610 | $7.20 | $83,579 | 90,780 | −11.3% | 10b5-1 |
| Jun 11, 2026 AForm 4 → | Jun 15, 8:16 pm EDT | Troy Edward WilsonDirector | 27,000 | — | — | 70,550 | — | 10b5-1 |
| Jun 11, 2026 AForm 4 → | Jun 15, 8:14 pm EDT | Brian M StuglikDirector | 27,000 | — | — | 121,958 | — | 10b5-1 |
| Jun 11, 2026 AForm 4 → | Jun 15, 8:13 pm EDT | Adrian SenderowiczDirector | 27,000 | — | — | 54,000 | — | 10b5-1 |
| Jun 11, 2026 AForm 4 → | Jun 15, 8:12 pm EDT | Michael Patrick MillerDirector | 27,000 | — | — | 81,000 | — | |
| Jun 11, 2026 AForm 4 → | Jun 15, 8:10 pm EDT | Jay M MoyesDirector | 27,000 | — | — | 80,322 | — | 10b5-1 |
| Jun 11, 2026 AForm 4 → | Jun 15, 8:09 pm EDT | Allison DorvalDirector | 27,000 | — | — | 102,390 | — | 10b5-1 |
| Jun 11, 2026 AForm 4 → | Jun 15, 8:07 pm EDT | Alessandra CesanoDirector | 27,000 | — | — | 68,850 | — | |
| Feb 6, 2019 AForm 4 → | Feb 8, 5:37 pm EST | Douglas M HuntSee Remarks | 9,900 | — | — | 9,900 | — | plan? |
| Feb 6, 2019 AForm 4 → | Feb 8, 5:34 pm EST | Richard Paul BryceSEE REMARKS | 9,900 | — | — | 39,185 | — | plan? |
| Feb 6, 2019 AForm 4 → | Feb 8, 5:30 pm EST | Alan H AuerbachPRESIDENT AND CEO, Director, 10% Owner | 39,215 | — | — | 4,204,682 | — | plan? |
| Feb 4, 2019 SForm 4 → | Feb 6, 4:38 pm EST | Charles R EylerSEE REMARKS | 87 | $27.64 | $2,405 | 31,957 | −0.27% | plan? |
| Feb 4, 2019 SForm 4 → | Feb 6, 4:34 pm EST | Richard Paul BryceSEE REMARKS | 89 | $27.77 | $2,472 | 29,285 | −0.30% | plan? |
| Feb 4, 2019 SForm 4 → | Feb 6, 4:30 pm EST | Alan H AuerbachPRESIDENT AND CEO, Director, 10% Owner | 345 | $27.80 | $9,591 | 4,165,467 | −0.01% | plan? |
| Jan 22, 2019 SForm 4 → | Jan 24, 4:54 pm EST | Steven LoChief Commercial Officer | 2,114 | $24.91 | $52,664 | 21,409 | −8.99% | plan? |
| Jan 22, 2019 SForm 4 → | Jan 24, 4:51 pm EST | Charles R EylerSEE REMARKS | 713 | $24.80 | $17,682 | 32,044 | −2.18% | plan? |
| Jan 22, 2019 SForm 4 → | Jan 24, 4:47 pm EST | Richard Paul BryceSEE REMARKS | 1,959 | $24.72 | $48,426 | 29,374 | −6.25% | plan? |
| Jan 22, 2019 SForm 4 → | Jan 24, 4:44 pm EST | Alan H AuerbachPRESIDENT AND CEO, Director, 10% Owner | 8,825 | $24.74 | $218,334 | 4,165,812 | −0.21% | plan? |
| Jan 3, 2019 SForm 4 → | Jan 4, 6:26 pm EST | Alan H AuerbachPRESIDENT AND CEO, Director, 10% Owner | 4,424 | $20.67 | $91,444 | 4,174,637 | −0.11% | plan? |
| Jan 3, 2019 SForm 4 → | Jan 4, 5:16 pm EST | Charles R EylerSEE REMARKS | 1,210 | $20.67 | $25,011 | 32,757 | −3.56% | plan? |
| Jan 3, 2019 SForm 4 → | Jan 4, 5:08 pm EST | Richard Paul BryceSEE REMARKS | 1,210 | $20.67 | $25,011 | 31,333 | −3.72% | plan? |
| Dec 3, 2018 SForm 4 → | Dec 4, 4:59 pm EST | Charles R EylerSEE REMARKS | 1,239 | $22.77 | $28,212 | 33,967 | −3.52% | plan? |
| Jul 20, 2018 SForm 4 → | Jul 24, 5:10 pm EDT | Steven LoChief Commercial Officer | 1,839 | $51.85 | $95,360 | 23,523 | −7.25% | plan? |
| Jul 20, 2018 SForm 4 → | Jul 24, 5:07 pm EDT | Charles R EylerSEE REMARKS | 610 | $51.95 | $31,690 | 35,206 | −1.70% | plan? |
| Jul 20, 2018 SForm 4 → | Jul 24, 5:03 pm EDT | Richard Paul BryceSEE REMARKS | 1,836 | $51.95 | $95,381 | 32,543 | −5.34% | plan? |
| Jul 20, 2018 SForm 4 → | Jul 24, 5:00 pm EDT | Alan H AuerbachPRESIDENT AND CEO, Director, 10% Owner | 12,520 | $52.00 | $651,020 | 4,179,061 | −0.30% | plan? |
| Jun 12, 2018 AForm 4 → | Jun 14, 7:29 pm EDT | Frank ZavrlDirector | 5,822 | — | — | 5,822 | — | plan? |
| Jun 12, 2018 AForm 4 → | Jun 14, 7:24 pm EDT | Troy Edward WilsonDirector | 5,822 | — | — | 6,172 | — | plan? |
| Jun 12, 2018 AForm 4 → | Jun 14, 7:16 pm EDT | Adrian SenderowiczDirector | 5,822 | — | — | 5,822 | — | plan? |
| Jun 12, 2018 AForm 4 → | Jun 14, 7:10 pm EDT | Jay M MoyesDirector | 5,822 | — | — | 5,822 | — | plan? |
| Jun 12, 2018 AForm 4 → | Jun 14, 6:36 pm EDT | Michael Patrick MillerDirector | 5,482 | — | — | 5,482 | — | plan? |
| Jun 1, 2018 SForm 4 → | Jun 4, 5:08 pm EDT | Charles R EylerSEE REMARKS | 1,211 | $53.00 | $64,183 | 35,816 | −3.27% | plan? |
| Feb 11, 2018 AForm 4/A → | Mar 7, 4:34 pm EST | Richard Paul BryceSEE REMARKS | 9,000 | — | — | 34,379 | — | plan? |
| Feb 11, 2018 AForm 4 → | Feb 13, 6:00 pm EST | Charles R EylerSEE REMARKS | 9,000 | — | — | 37,027 | — | plan? |
| Feb 11, 2018 AForm 4 → | Feb 13, 5:57 pm EST | Richard Paul BryceSEE REMARKS | 9,000 | — | — | 34,379 | — | plan? amended |
| Feb 11, 2018 AForm 4 → | Feb 13, 5:55 pm EST | Alan H AuerbachPRESIDENT AND CEO, Director, 10% Owner | 35,650 | — | — | 4,191,581 | — | plan? |
| Jan 22, 2018 SForm 4/A → | Aug 2, 4:33 pm EDT | Charles R EylerSEE REMARKS | 669 | $92.85 | $62,117 | 28,027 | −2.33% | plan? |
| Jan 22, 2018 SForm 4 → | Jan 24, 4:38 pm EST | Steven LoChief Commercial Officer | 1,858 | $92.85 | $172,515 | 25,362 | −6.83% | plan? |
| Jan 22, 2018 SForm 4 → | Jan 24, 4:36 pm EST | Charles R EylerSEE REMARKS | 669 | $92.85 | $62,117 | 28,027 | — | plan? amended |
| Jan 22, 2018 SForm 4 → | Jan 24, 4:33 pm EST | Richard Paul BryceSR VP, CLINICAL RESEARCH & DEV | 1,860 | $92.75 | $172,515 | 25,379 | −6.83% | plan? |
| Jan 22, 2018 SForm 4 → | Jan 24, 4:30 pm EST | Alan H AuerbachPRESIDENT AND CEO, Director, 10% Owner | 10,692 | $92.75 | $991,683 | 4,155,931 | −0.26% | plan? |
| Dec 1, 2017 SForm 4 → | Dec 5, 4:06 pm EST | Charles R EylerSEE REMARKS | 1,322 | $105.46 | $139,424 | 28,696 | −4.40% | plan? |
| Sep 29, 2017 SForm 4 → | Oct 2, 4:24 pm EDT | Richard Paul BryceSR VP, CLINICAL RESEARCH & DEV | 15,000 | $120.00 | $1,800,000 | 27,239 | −35.5% | plan? |
| Sep 29, 2017 MForm 4 → | Oct 2, 4:24 pm EDT | Richard Paul BryceSR VP, CLINICAL RESEARCH & DEV | 15,000 | $11.30 | $169,500 | 42,239 | — | plan? |
| Sep 6, 2017 SForm 4 → | Sep 8, 4:11 pm EDT | Richard Paul BryceSR VP, CLINICAL RESEARCH & DEV | 15,000 | $100.09 | $1,501,400 | 27,239 | −35.5% | plan? |
| Sep 6, 2017 MForm 4 → | Sep 8, 4:11 pm EDT | Richard Paul BryceSR VP, CLINICAL RESEARCH & DEV | 15,000 | $11.30 | $169,500 | 41,239 | — | plan? |
| Jul 20, 2017 SForm 4 → | Jul 24, 5:16 pm EDT | Steven LoChief Commercial Officer | 1,990 | $94.90 | $188,853 | 27,220 | −6.81% | plan? |
| Jul 20, 2017 SForm 4 → | Jul 24, 5:14 pm EDT | Charles R EylerSEE REMARKS | 662 | $95.15 | $62,991 | 30,018 | −2.16% | plan? |
| Jul 20, 2017 SForm 4 → | Jul 24, 5:10 pm EDT | Richard Paul BryceSR VP, CLINICAL RESEARCH & DEV | 1,998 | $94.48 | $188,777 | 27,239 | −6.83% | plan? |
| Jul 20, 2017 SForm 4 → | Jul 24, 5:07 pm EDT | Alan H AuerbachPRESIDENT AND CEO, Director, 10% Owner | 13,175 | $94.73 | $1,248,005 | 4,166,623 | −0.32% | plan? |
| Jul 3, 2017 SForm 4 → | Jul 14, 6:01 pm EDT | Richard Paul BryceSR VP, CLINICAL RESEARCH & DEV | 5,000 | $87.10 | $435,500 | 29,237 | −14.6% | plan? late |
| Jul 3, 2017 MForm 4 → | Jul 14, 6:01 pm EDT | Richard Paul BryceSR VP, CLINICAL RESEARCH & DEV | 5,000 | $11.30 | $56,500 | 34,237 | — | plan? late |
| Jun 8, 2017 SForm 4 → | Jun 12, 6:45 pm EDT | ADAGE CAPITAL PARTNERS GP, L.L.C. +410% Owner | 247,260 | $80.32 | $19,858,910 | 3,696,580 | −6.27% | plan? |
| Jun 1, 2017 SForm 4 → | Jun 5, 5:58 pm EDT | ADAGE CAPITAL PARTNERS GP, L.L.C. +410% Owner | 507,128 | $87.84 | $44,544,975 | 3,943,840 | −11.4% | plan? |
| May 31, 2017 AForm 4 → | Jun 1, 5:00 pm EDT | Charles R EylerSEE REMARKS | 21,000 | — | — | 30,680 | — | plan? |
| May 24, 2017 SForm 4 → | May 26, 4:40 pm EDT | ADAGE CAPITAL PARTNERS GP, L.L.C. +410% Owner | 1,235,700 | $75.38 | $93,144,268 | 4,450,968 | −21.7% | plan? |
| Feb 1, 2017 SForm 4 → | Feb 2, 5:43 pm EST | Robert CharnasOther | 3,008 | $31.83 | $95,755 | 26,453 | −10.2% | plan? |
| Jan 20, 2017 SForm 4/A → | Feb 2, 5:41 pm EST | Robert CharnasOther | 2,239 | $33.24 | $74,413 | 29,461 | −7.06% | plan? |
| Jan 20, 2017 SForm 4 → | Jan 24, 5:56 pm EST | Steven LoChief Commercial Officer | 2,290 | $33.24 | $76,108 | 29,210 | −7.27% | plan? |
| Jan 20, 2017 SForm 4 → | Jan 24, 5:53 pm EST | Charles R EylerSEE REMARKS | 820 | $33.24 | $27,253 | 9,680 | −7.81% | plan? |
| Jan 20, 2017 SForm 4 → | Jan 24, 5:52 pm EST | Robert CharnasOther | 2,293 | $33.24 | $76,208 | 29,407 | −7.23% | plan? amended |
| Jan 20, 2017 SForm 4 → | Jan 24, 5:51 pm EST | Richard Paul BryceSR VP, CLINICAL RESEARCH & DEV | 2,293 | $33.24 | $76,208 | 29,237 | −7.27% | plan? |
| Jan 20, 2017 SForm 4 → | Jan 24, 5:49 pm EST | Alan H AuerbachPRESIDENT AND CEO, Director, 10% Owner | 10,202 | $33.24 | $339,064 | 4,179,798 | −0.24% | plan? |
| Oct 14, 2016 AForm 4 → | Oct 14, 9:19 pm EDT | Steven LoChief Commercial Officer | 31,500 | — | — | 31,500 | — | plan? |
| Oct 14, 2016 AForm 4 → | Oct 14, 9:18 pm EDT | Charles R EylerSEE REMARKS | 10,500 | — | — | 10,500 | — | plan? |
| Oct 14, 2016 AForm 4 → | Oct 14, 9:16 pm EDT | Robert CharnasOther | 31,500 | — | — | 31,700 | — | plan? |
| Oct 14, 2016 AForm 4 → | Oct 14, 9:12 pm EDT | Richard Paul BryceSR VP, CLINICAL RESEARCH & DEV | 31,500 | — | — | 31,530 | — | plan? |
| Oct 14, 2016 AForm 4 → | Oct 14, 9:09 pm EDT | Alan H AuerbachPRESIDENT AND CEO, Director, 10% Owner | 150,000 | — | — | 4,190,000 | — | plan? |
| Jul 6, 2015 SForm 4 → | Jul 8, 5:50 pm EDT | Richard Paul BryceSR VP, CLINICAL RESEARCH & DEV | 3,000 | $110.03 | $330,084 | 30 | −99.0% | plan? |
| Jul 6, 2015 MForm 4 → | Jul 8, 5:50 pm EDT | Richard Paul BryceSR VP, CLINICAL RESEARCH & DEV | 3,000 | $11.30 | $33,900 | 3,030 | — | plan? |
| Apr 9, 2014 PForm 4 → | May 21, 2015, 4:51 pm EDT | Richard Paul BryceSR VP, CLINICAL RESEARCH & DEV | 30 | $82.81 | $2,484 | 30 | — | plan? late |
Reported at this company — derivatives (options, RSUs, warrants)
| Trade | Reported (ET) | Insider | Shares | Avg price | Total | Owned after | Δ stake | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 14, 2026 MForm 4 → | Sep 16, 9:06 pm EDT | Alessandra CesanoDirector | 50,000 | — | — | 50,000 | — | 10b5-1 |
| Feb 6, 2019 AForm 4 → | Feb 8, 5:39 pm EST | Steven LoChief Commercial Officer | 36,300 | — | — | 36,300 | — | |
| Feb 6, 2019 AForm 4 → | Feb 8, 5:37 pm EST | Douglas M HuntSee Remarks | 15,400 | — | — | 15,400 | — | |
| Feb 6, 2019 AForm 4 → | Feb 8, 5:34 pm EST | Richard Paul BryceSEE REMARKS | 15,400 | — | — | 15,400 | — | |
| Feb 6, 2019 AForm 4 → | Feb 8, 5:30 pm EST | Alan H AuerbachPRESIDENT AND CEO, Director, 10% Owner | 62,634 | — | — | 62,634 | — | |
| Nov 11, 2018 AForm 4 → | Nov 13, 7:25 pm EST | Maximo F NouguesChief Financial Officer | 90,000 | — | — | 90,000 | — | |
| Feb 23, 2018 AForm 4 → | Feb 27, 5:30 pm EST | Michael Patrick MillerDirector | 17,626 | — | — | 17,626 | — | |
| Feb 11, 2018 AForm 4 → | Feb 13, 6:02 pm EST | Steven LoChief Commercial Officer | 33,000 | — | — | 33,000 | — | |
| Feb 11, 2018 AForm 4 → | Feb 13, 6:00 pm EST | Charles R EylerSEE REMARKS | 14,000 | — | — | 14,000 | — | |
| Feb 11, 2018 AForm 4 → | Feb 13, 5:57 pm EST | Richard Paul BryceSEE REMARKS | 14,000 | — | — | 14,000 | — | amended |
| Feb 11, 2018 AForm 4 → | Feb 13, 5:55 pm EST | Alan H AuerbachPRESIDENT AND CEO, Director, 10% Owner | 56,940 | — | — | 56,940 | — | |
| Jan 16, 2018 AForm 4 → | Jan 17, 4:31 pm EST | Douglas M HuntSee Remarks | 90,000 | — | — | 90,000 | — | |
| Sep 29, 2017 MForm 4 → | Oct 2, 4:24 pm EDT | Richard Paul BryceSR VP, CLINICAL RESEARCH & DEV | 15,000 | — | — | 67,000 | — | |
| Sep 6, 2017 MForm 4 → | Sep 8, 4:11 pm EDT | Richard Paul BryceSR VP, CLINICAL RESEARCH & DEV | 15,000 | — | — | 82,000 | — | |
| Jul 3, 2017 MForm 4 → | Jul 14, 6:01 pm EDT | Richard Paul BryceSR VP, CLINICAL RESEARCH & DEV | 5,000 | — | — | 97,000 | — | late |
| Jun 12, 2017 AForm 4 → | Jun 14, 9:19 pm EDT | Adrian SenderowiczDirector | 7,604 | — | — | 7,604 | — | |
| Jun 12, 2017 AForm 4 → | Jun 14, 6:13 pm EDT | Frank ZavrlDirector | 7,604 | — | — | 7,604 | — | |
| Jun 12, 2017 AForm 4 → | Jun 14, 6:11 pm EDT | Troy Edward WilsonDirector | 7,604 | — | — | 7,604 | — | |
| Jun 12, 2017 AForm 4 → | Jun 14, 6:10 pm EDT | Jay M MoyesDirector | 7,604 | — | — | 7,604 | — | |
| Feb 16, 2017 AForm 4 → | Feb 21, 4:47 pm EST | Robert CharnasSee Remarks | 15,750 | — | — | 15,750 | — | |
| Feb 16, 2017 AForm 4 → | Feb 21, 4:45 pm EST | Richard Paul BryceSR VP, CLINICAL RESEARCH & DEV | 31,500 | — | — | 31,500 | — | |
| Feb 16, 2017 AForm 4 → | Feb 21, 4:43 pm EST | Steven LoChief Commercial Officer | 31,500 | — | — | 31,500 | — | |
| Feb 16, 2017 AForm 4 → | Feb 21, 4:41 pm EST | Charles R EylerSEE REMARKS | 31,500 | — | — | 31,500 | — | |
| Feb 16, 2017 AForm 4 → | Feb 21, 4:39 pm EST | Alan H AuerbachPRESIDENT AND CEO, Director, 10% Owner | 70,000 | — | — | 70,000 | — | |
| Nov 14, 2016 AForm 4 → | Nov 16, 5:53 pm EST | Frank ZavrlDirector | 10,000 | — | — | 10,000 | — | |
| Nov 14, 2016 AForm 4 → | Nov 16, 5:51 pm EST | Troy Edward WilsonDirector | 10,000 | — | — | 10,000 | — | |
| Nov 14, 2016 AForm 4 → | Nov 16, 5:49 pm EST | Adrian SenderowiczDirector | 10,000 | — | — | 10,000 | — | |
| Nov 14, 2016 AForm 4 → | Nov 16, 5:48 pm EST | Jay M MoyesDirector | 10,000 | — | — | 10,000 | — | |
| Jul 1, 2016 AForm 4 → | Jul 5, 5:07 pm EDT | Robert CharnasOther | 90,000 | — | — | 90,000 | — | |
| May 25, 2016 AForm 4 → | May 27, 4:20 pm EDT | Steven LoChief Commercial Officer | 30,000 | — | — | 30,000 | — | |
| May 25, 2016 AForm 4 → | May 27, 4:18 pm EDT | Charles R EylerSEE REMARKS | 30,000 | — | — | 30,000 | — | |
| May 25, 2016 AForm 4 → | May 27, 4:15 pm EDT | Richard Paul BryceSR VP, CLINICAL RESEARCH & DEV | 41,250 | — | — | 41,250 | — | |
| May 25, 2016 AForm 4 → | May 27, 4:12 pm EDT | Alan H AuerbachPRESIDENT AND CEO, Director, 10% Owner | 66,667 | — | — | 66,667 | — | |
| Apr 15, 2016 AForm 4 → | Apr 18, 4:56 pm EDT | Richard Benton PhillipsSee Remarks | 25,000 | — | — | 25,000 | — | |
| Apr 14, 2016 AForm 4 → | Apr 15, 4:43 pm EDT | Frank ZavrlDirector | 10,000 | — | — | 10,000 | — | |
| Apr 14, 2016 AForm 4 → | Apr 15, 4:40 pm EDT | Adrian SenderowiczDirector | 10,000 | — | — | 10,000 | — | |
| Dec 16, 2015 AForm 4 → | Dec 18, 9:43 pm EST | Frank ZavrlDirector | 10,000 | — | — | 10,000 | — | |
| Dec 16, 2015 AForm 4 → | Dec 17, 5:57 pm EST | Troy Edward WilsonDirector | 10,000 | — | — | 10,000 | — | |
| Dec 16, 2015 AForm 4 → | Dec 17, 5:55 pm EST | Adrian SenderowiczDirector | 10,000 | — | — | 10,000 | — | |
| Dec 16, 2015 AForm 4 → | Dec 17, 5:52 pm EST | Jay M MoyesDirector | 10,000 | — | — | 10,000 | — | |
| Oct 8, 2015 AForm 4 → | Oct 9, 5:00 pm EDT | Charles R EylerSEE REMARKS | 31,500 | — | — | 31,500 | — | |
| Oct 7, 2015 AForm 4 → | Oct 9, 4:55 pm EDT | Alan H AuerbachPRESIDENT AND CEO, Director, 10% Owner | 150,000 | — | — | 150,000 | — | |
| Sep 8, 2015 AForm 4 → | Sep 10, 7:55 pm EDT | Frank ZavrlDirector | 40,000 | — | — | 10,000 | — | |
| Sep 8, 2015 AForm 4 → | Sep 10, 6:50 pm EDT | Adrian SenderowiczDirector | 10,000 | — | — | 10,000 | — | |
| Sep 8, 2015 AForm 4 → | Sep 10, 6:37 pm EDT | Troy Edward WilsonDirector | 10,000 | — | — | 10,000 | — | |
| Sep 8, 2015 AForm 4 → | Sep 10, 6:34 pm EDT | Steven LoChief Commercial Officer | 150,000 | — | — | 150,000 | — | |
| Aug 26, 2015 AForm 4 → | Aug 27, 6:17 pm EDT | Jay M MoyesDirector | 20,000 | — | — | 20,000 | — | |
| Aug 11, 2015 AForm 4 → | Aug 13, 9:25 pm EDT | Adrian SenderowiczDirector | 30,000 | — | — | 30,000 | — | |
| Aug 3, 2015 AForm 4 → | Aug 4, 7:35 pm EDT | Richard Paul BryceSR VP, CLINICAL RESEARCH & DEV | 31,500 | — | — | 31,500 | — | |
| Jul 6, 2015 MForm 4 → | Jul 8, 5:50 pm EDT | Richard Paul BryceSR VP, CLINICAL RESEARCH & DEV | 3,000 | — | — | 102,000 | — |